Making Best Practice, Every Day Practice
This resource is fully searchable using the search box at the top of the page, or to narrow down your selection using filters click on 'Knowledge hub' in the main navigation.
Here you will find:
More than 500 articles especially written by colleagues to support your care of patients with the cardiovascular diseases commonly seen in primary care.
Articles on the diagnosis and treatment of patients with cardiovascular conditions such as:
…and more.
Simple and informative infographics which will answer questions such as “How do these drugs work?”, “What causes this heart condition?” and much more.
Pharmacists in the ethnically diverse city of Leicester piloted Healthy Life Checks in inner-city pharmacies, forpeople aged 40-74. Pharmacists conducted checks including blood pressure, weight and glucose measurementand gave lifestyle advice. We present here the findings from semi-structured telephone interviews conductedwith pharmacists and service users.
Epidemiological research has clearly established that many risk factors contribute to cardiovascular disease(CVD). Some of them are modifiable, and treatment decisions are based on the level of risk determined by risk assessment. Positive lifestyle changes are crucial to the prevention and management of CVD, and can result in substantial risk reduction. These changes can include smoking cessation interventions, acardioprotective dietary pattern and increased physical activity. However, lifestyle changes are challenging forboth the healthcare professional and the patient, and behavioural counselling and regular follow-ups are often required to overcome barriers, encourage adherence and assist in the achievement of long-term lifestyle goals.This article aims to provide practitioners with a concise guide to the role and impact of lifestyle changesbased on recommendations from six of the most up-to-date clinical practice guidelines for prevention ofcardiovascular disease.
The first general practitioners with a special interest (GPwSI) in cardiology services were set up more than 10 years ago but there is little information available on the national level about service provision. The authors invited all GPwSIs in cardiology to complete a survey detailing their qualifications and experience, range of services provided, capacity and clinical governance. The results are presented here.
Cardiovascular disease continues to be the leading cause of premature morbidity and mortality in the UK.1 Primary prevention not only is cost-effective but is endorsed as a priority by healthcare systems in the UK, and indeed globally. We describe here a targeted prevention service, which showed that the modifiable risk factors of obesity and overweight, smoking and low levels of high-density lipoprotein cholesterol were highly prevalent in first-degree relatives of patients with premature coronary heart disease.
Worsening dyspnoea is a very common presenting complaint in the community; the causes varyhugely. We present a case of a patient with worsening dyspnoea and a positional change in hissymptoms who was found to have a left atrial myxoma.
We hypothesised that practice heart failure registers may not be complete or robust due to patients not always being allocated the correct READ codes. We set up a project which improved practice heart failure registers. Ensuring practices have robust registers, by improving clinical coding in general practice, means more accurate prevalence levels can inform planning and commissioning of heart failure services.
Aortic stenosis (AS) is the commonest cardiac valve disease in developed countries, with aortic sclerosis affecting 26% of people aged 65 and over and severe AS occurring in 3% of people over 75 years. It will become more prevalent with the ageing population. Symptoms include dyspnoea and chest pain, but these are often missed so many patients are currently undiagnosed. Once symptoms occur, prognosis is poor, with average survival being only two to three years.Aortic valve replacement is the only effective treatment for severe, symptomatic AS and is recommended in both European and US guidelines, but many older patients with co-morbidities are currently considered unsuitable or too high-risk for open-heart surgery. The development of transcatheter aortic valve implantation (TAVI) offers an effective treatment option for these patients. Latest figures show the number of patients undergoing TAVI in the UK is below that recommended by the National Institute for Health and Clinical Excellence (NICE) and the rate in other European countries, indicating scope for increased referrals and use of this procedure to improve outcomes.
Managing heart failure requires a holistic approach: as well as optimal medical treatment, patients and their families need to have a sufficient understanding of the condition. There also needs to be a service to deliver this care. Heart failure affects about 0.5% of the population, depending on the age of the population, so each general practice has a manageable number of patients. However, the expertise and confidence needed to deliver optimal care to heart failure patients and their families are not widely held in primary care. There is largely a reliance on secondary care to provide community services, led by consultants and delivered by specialist nurses. Within this system patients are usually well served, but sometimes patients fall between the community service and general practice. In Central Manchester there is no community heart failure service. About one in five patients with heart failure were being admitted each year, indicating that heart failure management in the community needed to improve.
There is emerging evidence that heart rate control is an important element in the management of people with heart failure. The major beta-blocker trials have shown improved mortality and reduced hospitalisation when patients with impaired left ventricular (LV) function are managed with optimal doses. In a meta-analysis of these trials, McAlister et al. have shown a correlation between heart rate control and improved outcomes.1 Beta-blockers may have other actions apart from heart rate control; for instance, they may be anti-arrhythmic or have some other mechanisms for their action. Ivabradine, whose only function is heart rate control, has also shown a reduction in hospitalisation for heart failure.2 Heart rate is additionally an indicator of optimal beta-blockade3, and so may be a proxy for optimal medical treatment.
Men and women with cardiovascular disease are currently treated with multiple medicationsto reduce their cardiovascular risk. Although the links between erectile dysfunction (ED) andcoronary heart disease (CHD) are well established and ED often precedes the onset of CHD by3-5 years, few men in UK general practice are asked about their erections prior tocommencement of therapy for cardiovascular disease. The presumption is often that if thepatient has a sexual problem, then he will mention it and at that point the therapy can bechanged. There are two drawbacks with this approach: first, men do not readily volunteersexual problems, and second, unless the therapy change is made quickly, the problem isunlikely to resolve.5 Physicians must be aware that in many cases, such as the use of betablockersafter acute myocardial infarction, the appropriate management of the cardiaccondition is the major priority.
Echocardiography (ECHO) is the “gold standard” test in the diagnosis of heart failure. Brain natriuretic peptide (BNP) can be helpful to rule outpatients who do not require ECHO. This study used an elevated level of Nterminal prohormone BNP (NT-proBNP) as a criterion for referral to a new community heart failure clinic. Results showed that NT-proBNP could be a useful test in the management of heart failure. The researchers propose to institute age- and sex-related cut-offs to refine its place in the patient care pathway.
A unique new e-platform for primary care
By continuing to this site you are confirming that you are a healthcare professional and are opting into the use of cookies.